Disc Medicine Completes Phase 3 APOLLO Trial Enrollment for Bitopertin

Key Facts

1Disc Medicine announced the completion of participant enrollment in the Phase 3 APOLLO trial of bitopertin.

2The study was expanded from 150 to 183 participants due to high demand from patients and physicians.

3The trial targets Erythropoietic Protoporphyria (EPP), a serious hematologic disease.

Disc Medicine, Inc. (NASDAQ: IRON) has announced the successful completion of participant enrollment for its pivotal Phase 3 APOLLO clinical trial. The trial evaluates bitopertin as a potential treatment for Erythropoietic Protoporphyria (EPP), a serious and rare hematologic disorder. Due to significant interest from both patients and healthcare providers, the company expanded the study size from 150 to 183 participants. This milestone marks a critical step forward in the clinical development path toward potential regulatory approval and commercialization. The successful randomization and dosing of the final participant significantly de-risks the project's timeline and demonstrates strong operational execution. Investors view the completion of Phase 3 enrollment as a positive indicator for the company's progress within the biotech sector.